1194-06-5

Basic information

• Product Name: CYCLOPENTYL-UREA
• Synonyms: 1-Cyclopentylurea;N-Cyclopentylurea;1-Cyclopentylurea（WS202893）
• CAS NO: 1194-06-5
• Molecular Formula: C6H12N2O
• Molecular Weight: 128.1723
• Mol File: 1194-06-5.mol

Chemical Properties

• Boiling Point: 220.3°Cat760mmHg
• Flash Point: 87°C
• Appearance: /
• Density: 1.08g/cm³
• Vapor Pressure: 0.114mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: CYCLOPENTYL-UREA(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPENTYL-UREA(1194-06-5)
• EPA Substance Registry System: CYCLOPENTYL-UREA(1194-06-5)

Safety Data

• Hazardous Substances Data: 1194-06-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Manufacturing:
Cyclopentyl-Urea is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
As an intermediate in organic synthesis, Cyclopentyl-Urea contributes to the creation of a wide range of chemical products. Its cyclopentyl-modified urea structure can be further reacted or modified to produce other valuable organic compounds for various industries.

InChI:InChI=1/C6H12N2O/c7-6(9)8-5-3-1-2-4-5/h5H,1-4H2,(H3,7,8,9)

Upstream product

• 142-29-0 cyclopentene 
• 57-13-6 urea 
• 1118-02-1 trimethylsilyl isocyanate 
• 1003-03-8 Cyclopentamine 

Relevant articles and documents

Nitrogenous condensed heterocyclic compound as well as preparation method, intermediate, composition and application thereof

The invention discloses a nitrogenous condensed heterocyclic compound as well as a preparation method, an intermediate, a composition and application thereof. The compound disclosed by the invention has high inhibition activity for different subtypes of CDK (Cyclin-Dependent Kinase) at a molecular level, has good inhibition activity on breast cancer cells at a cell level, has a remarkable proliferation inhibition function on tumor cells related to cyclin-dependent kinase activity at an animal level, is good in liver microsome stability upon human beings, mice, and the like, is good in in-vivoabsorption in mice and rats, is high in bioavailability and is good in druggability.

PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

Amidomercuriation: A General Addition of Amides and Related Compounds to Olefins

The addition of different carboxamides and related compounds such as urethane or urea to olefins using mercury(II) nitrate followed by sodium borohydride reduction to give the corresponding N-substituted amides, urethanes, or ureas, respectively, is described.The monoalkylated ureas, through the same amidomercuriation-demercuriation procedure, yield symmetrical and unsymmetrical N,N'-disubstituted ureas.This amidomercuriation-demercuriation process provides a new, convenient, and general method for the Markovnikov amidation of carbon-carbon double bonds.